vs
Side-by-side financial comparison of FTAI Infrastructure Inc. (FIP) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Pacira BioSciences, Inc. is the larger business by last-quarter revenue ($177.4M vs $143.5M, roughly 1.2× FTAI Infrastructure Inc.). Pacira BioSciences, Inc. runs the higher net margin — 1.6% vs -68.1%, a 69.7% gap on every dollar of revenue. On growth, FTAI Infrastructure Inc. posted the faster year-over-year revenue change (77.7% vs 5.0%). Over the past eight quarters, FTAI Infrastructure Inc.'s revenue compounded faster (31.9% CAGR vs -0.2%).
FTAI Infrastructure Inc. owns, operates and invests in high-quality critical infrastructure assets across core sectors including transportation logistics, midstream energy, and power generation. It primarily serves North American markets, focusing on assets with stable long-term cash flows, contracted revenue streams, and strong market positions to deliver sustainable returns for stakeholders.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
FIP vs PCRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $143.5M | $177.4M |
| Net Profit | $-97.7M | $2.9M |
| Gross Margin | — | — |
| Operating Margin | -45.7% | 3.9% |
| Net Margin | -68.1% | 1.6% |
| Revenue YoY | 77.7% | 5.0% |
| Net Profit YoY | 21.6% | — |
| EPS (diluted) | $-1.04 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $177.4M | ||
| Q4 25 | $143.5M | $196.9M | ||
| Q3 25 | $140.6M | $179.5M | ||
| Q2 25 | $122.3M | $181.1M | ||
| Q1 25 | $96.2M | $168.9M | ||
| Q4 24 | $80.8M | $187.3M | ||
| Q3 24 | $83.3M | $168.6M | ||
| Q2 24 | $84.9M | $178.0M |
| Q1 26 | — | $2.9M | ||
| Q4 25 | $-97.7M | — | ||
| Q3 25 | $-104.5M | $5.4M | ||
| Q2 25 | $-70.0M | $-4.8M | ||
| Q1 25 | $120.2M | $4.8M | ||
| Q4 24 | $-124.7M | — | ||
| Q3 24 | $-43.0M | $-143.5M | ||
| Q2 24 | $-48.1M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | 79.5% | ||
| Q3 25 | — | 80.9% | ||
| Q2 25 | — | 77.4% | ||
| Q1 25 | — | 79.7% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 76.9% | ||
| Q2 24 | — | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | -45.7% | 1.2% | ||
| Q3 25 | -70.8% | 3.5% | ||
| Q2 25 | -56.4% | 4.7% | ||
| Q1 25 | 81.8% | 1.2% | ||
| Q4 24 | -152.7% | 13.2% | ||
| Q3 24 | -51.7% | -82.8% | ||
| Q2 24 | -56.4% | 15.9% |
| Q1 26 | — | 1.6% | ||
| Q4 25 | -68.1% | — | ||
| Q3 25 | -74.4% | 3.0% | ||
| Q2 25 | -57.2% | -2.7% | ||
| Q1 25 | 125.0% | 2.8% | ||
| Q4 24 | -154.4% | — | ||
| Q3 24 | -51.6% | -85.1% | ||
| Q2 24 | -56.7% | 10.6% |
| Q1 26 | — | $0.07 | ||
| Q4 25 | $-1.04 | $0.05 | ||
| Q3 25 | $-1.38 | $0.12 | ||
| Q2 25 | $-0.73 | $-0.11 | ||
| Q1 25 | $0.89 | $0.10 | ||
| Q4 24 | $-1.21 | $0.38 | ||
| Q3 24 | $-0.45 | $-3.11 | ||
| Q2 24 | $-0.52 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $57.4M | $144.3M |
| Total DebtLower is stronger | $3.8B | — |
| Stockholders' EquityBook value | $21.3M | $653.9M |
| Total Assets | $5.7B | $1.2B |
| Debt / EquityLower = less leverage | 176.99× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $144.3M | ||
| Q4 25 | $57.4M | $238.4M | ||
| Q3 25 | $34.7M | $246.3M | ||
| Q2 25 | $33.6M | $445.9M | ||
| Q1 25 | $26.3M | $493.6M | ||
| Q4 24 | $27.8M | $484.6M | ||
| Q3 24 | $20.3M | $453.8M | ||
| Q2 24 | $33.1M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | $3.8B | $372.2M | ||
| Q3 25 | $3.7B | $376.7M | ||
| Q2 25 | $3.1B | $580.5M | ||
| Q1 25 | $2.8B | $583.4M | ||
| Q4 24 | $1.6B | $585.3M | ||
| Q3 24 | $1.5B | — | ||
| Q2 24 | $1.6B | — |
| Q1 26 | — | $653.9M | ||
| Q4 25 | $21.3M | $693.1M | ||
| Q3 25 | $181.1M | $727.2M | ||
| Q2 25 | $375.5M | $757.8M | ||
| Q1 25 | $476.2M | $798.5M | ||
| Q4 24 | $202.7M | $778.3M | ||
| Q3 24 | $370.8M | $749.6M | ||
| Q2 24 | $394.8M | $879.3M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $5.7B | $1.3B | ||
| Q3 25 | $5.5B | $1.3B | ||
| Q2 25 | $4.4B | $1.5B | ||
| Q1 25 | $4.1B | $1.6B | ||
| Q4 24 | $2.4B | $1.6B | ||
| Q3 24 | $2.4B | $1.5B | ||
| Q2 24 | $2.5B | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | 176.99× | 0.54× | ||
| Q3 25 | 20.59× | 0.52× | ||
| Q2 25 | 8.21× | 0.77× | ||
| Q1 25 | 5.79× | 0.73× | ||
| Q4 24 | 7.84× | 0.75× | ||
| Q3 24 | 4.14× | — | ||
| Q2 24 | 3.94× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-2.8M | — |
| Free Cash FlowOCF − Capex | $-68.6M | — |
| FCF MarginFCF / Revenue | -47.8% | — |
| Capex IntensityCapex / Revenue | 45.9% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-398.5M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-2.8M | $43.7M | ||
| Q3 25 | $-24.4M | $60.8M | ||
| Q2 25 | $-5.2M | $12.0M | ||
| Q1 25 | $-85.7M | $35.5M | ||
| Q4 24 | $-8.1M | $33.1M | ||
| Q3 24 | $14.2M | $53.9M | ||
| Q2 24 | $-17.6M | $53.2M |
| Q1 26 | — | — | ||
| Q4 25 | $-68.6M | $43.5M | ||
| Q3 25 | $-90.7M | $57.0M | ||
| Q2 25 | $-87.5M | $9.3M | ||
| Q1 25 | $-151.7M | $26.9M | ||
| Q4 24 | $-34.3M | $31.0M | ||
| Q3 24 | $-11.7M | $49.8M | ||
| Q2 24 | $-32.1M | $51.6M |
| Q1 26 | — | — | ||
| Q4 25 | -47.8% | 22.1% | ||
| Q3 25 | -64.5% | 31.7% | ||
| Q2 25 | -71.6% | 5.1% | ||
| Q1 25 | -157.7% | 15.9% | ||
| Q4 24 | -42.4% | 16.6% | ||
| Q3 24 | -14.0% | 29.6% | ||
| Q2 24 | -37.9% | 29.0% |
| Q1 26 | — | — | ||
| Q4 25 | 45.9% | 0.1% | ||
| Q3 25 | 47.2% | 2.2% | ||
| Q2 25 | 67.3% | 1.5% | ||
| Q1 25 | 68.6% | 5.1% | ||
| Q4 24 | 32.5% | 1.1% | ||
| Q3 24 | 31.1% | 2.4% | ||
| Q2 24 | 17.2% | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 11.20× | ||
| Q2 25 | — | — | ||
| Q1 25 | -0.71× | 7.37× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 2.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FIP
| Power Revenues | $45.9M | 32% |
| Rail Revenue | $44.6M | 31% |
| Service Other | $22.8M | 16% |
| Gas Revenues | $15.3M | 11% |
| Roadside Services Revenues | $11.5M | 8% |
| Rapauno | $1.2M | 1% |
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
